Immpact's bispecific CAR T therapy IMPT-514 cleared by FDA to enter clinic for SLE
Aug. 16, 2023
Immpact Bio USA Inc. has received FDA clearance of its IND application for IMPT-514, a bispecific CD19/CD20 chimeric antigen receptor (CAR) T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
